The online version of this article (doi:10.1186/1465-9921-15-18) contains supplementary material, which is available to authorized users.
S.M.R served as PI for CF Clinical Trials sponsored by Vertex Pharmaceuticals and Novartis. He has received COPD-related grant funding from NHLBI and Forest Research Institute. M.T.D has served on COPD-related advisory boards for Ikaria, Forest, GlaxoSmithKline and Boehringer Ingelheim. He has served as site PI for contracted COPD clinical trials sponsored by Aeris, Centocor, Pfizer, Otsuka, Pulmonx, GlaxoSmithKline and Boehringer Ingelheim. He has received COPD-related grant funding from Forest, GlaxoSmithKline and NHLBI.
SVR, JHT, MTD, and SMR conceived of the experiments; SVR, JHT, and SKGP, conducted the research; SVR, JHT, RO, PF, MTD, MTD, and SMR analyzed the data; SVR and SMR wrote the manuscript; SMR and MTD supervised the project. All authors read and approve the final manuscript.
Cigarette smoking causes Chronic Obstructive Pulmonary Disease (COPD), the 3rd leading cause of death in the U.S. CFTR ion transport dysfunction has been implicated in COPD pathogenesis, and is associated with chronic bronchitis. However, susceptibility to smoke induced lung injury is variable and the underlying genetic contributors remain unclear. We hypothesized that presence of CFTR mutation heterozygosity may alter susceptibility to cigarette smoke induced CFTR dysfunction. Consequently, COPD patients with chronic bronchitis may have a higher rate of CFTR mutations compared to the general population.
Primary human bronchial epithelial cells derived from F508del CFTR heterozygotes and mice with (CFTR+/-) and without (CFTR+/+) CFTR heterozygosity were exposed to whole cigarette smoke (WCS); CFTR-dependent ion transport was assessed by Ussing chamber electrophysiology and nasal potential difference measurements, respectively. Caucasians with COPD and chronic bronchitis, age 40 to 80 with FEV1/FVC < 0.70 and FEV1 < 60% predicted, were selected for genetic analysis from participants in the NIH COPD Clinical Research Network’s Azithromycin for Prevention of Exacerbations of COPD in comparison to 32,900 Caucasian women who underwent prenatal genetic testing. Genetic analysis involved an allele-specific genotyping of 89 CFTR mutations.
Exposure to WCS caused a pronounced reduction in CFTR activity in both CFTR (+/+) cells and F508del CFTR (+/-) cells; however, neither the degree of decrement (44.7% wild-type vs. 53.5% F508del heterozygous, P = NS) nor the residual CFTR activity were altered by CFTR heterozygosity. Similarly, WCS caused a marked reduction in CFTR activity measured by NPD in both wild type and CFTR heterozygous mice, but the severity of decrement (91.1% wild type vs. 47.7% CF heterozygous, P = NS) and the residual activity were not significantly affected by CFTR genetic status. Five of 127 (3.9%) COPD patients with chronic bronchitis were heterozygous for CFTR mutations which was not significantly different from controls (4.5%) (P = NS).
The magnitude of WCS induced reductions in CFTR activity was not affected by the presence of CFTR mutation heterozygosity. CFTR mutations do not increase the risk of COPD with chronic bronchitis. CFTR dysfunction due to smoking is primarily an acquired phenomenon and is not affected by the presence of congenital CFTR mutations.
Minino AM, Murphy SL, Xu J, Kochanek KD: Deaths: final data for 2008. Natl Vital Stat Rep. 2011, 59: 1-126.
Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG: Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med. 2002, 136: 270-279. 10.7326/0003-4819-136-4-200202190-00006. PubMedCrossRef
Kim DK, Cho MH, Hersh CP, Lomas DA, Miller BE, Kong X, Bakke P, Gulsvik A, Agusti A, Wouters E, et al: Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012, 186: 1238-1247. 10.1164/rccm.201206-1013OC. PubMedPubMedCentralCrossRef
Varga K, Goldstein RF, Jurkuvenaite A, Chen L, Matalon S, Sorscher EJ, Bebok Z, Collawn JF: Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J. 2008, 410: 555-564. 10.1042/BJ20071420. PubMedPubMedCentralCrossRef
Cystic Fibrosis Foundation C: Cystic Fibrosis Patient Registry. 2012
Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, Levin E, Raju SV, Li Y, Mazur M, et al: A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One. 2012, 7: e39809-10.1371/journal.pone.0039809. PubMedPubMedCentralCrossRef
Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, Zeman KL, Worthington EN, Gentzsch M, Kreda SM, Cholon D, et al: Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J. 2012, 26: 533-545. 10.1096/fj.11-192377. PubMedPubMedCentralCrossRef
Raju SV, Jackson PL, Courville CA, McNicholas CM, Sloane PA, Sabbatini G, Tidwell S, Tang LP, Liu B, Fortenberry JA, et al: Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med. 2013, 188: 1321-1330. 10.1164/rccm.201304-0733OC. PubMedPubMedCentralCrossRef
Divac A, Nikolic A, Mitic-Milikic M, Nagorni-Obradovic L, Petrovic-Stanojevic N, Dopudja-Pantic V, Nadaskic R, Savic A, Radojkovic D: High frequency of the R75Q CFTR variation in patients with chronic obstructive pulmonary disease. J Cyst Fibros. 2004, 3: 189-191. 10.1016/j.jcf.2004.05.049. PubMedCrossRef
Stankovic M, Nikolic A, Divac A, Tomovic A, Petrovic-Stanojevic N, Andjelic M, Dopudja-Pantic V, Surlan M, Vujicic I, Ponomarev D, et al: The CFTR M470V gene variant as a potential modifier of COPD severity: study of Serbian population. Genet Test. 2008, 12: 357-362. 10.1089/gte.2007.0069. PubMedCrossRef
Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al: Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009, 106: 18825-18830. 10.1073/pnas.0904709106. PubMedPubMedCentralCrossRef
Pyle LC, Ehrhardt A, Mitchell LH, Fan L, Ren A, Naren AP, Li Y, Clancy JP, Bolger GB, Sorscher EJ, Rowe SM: Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators. Am J Physiol Lung Cell Mol Physiol. 2011, 301: L587-L597. 10.1152/ajplung.00465.2010. PubMedPubMedCentralCrossRef
Lambert JA, Raju SV, Tang LP, McNicholas-Bevensee C, Li Y, Clifford CA, Dransfield MT, Bolger GB, Rowe S, Lambert JA, Raju SV, Tang LP, McNicholas-Bevensee C, Li Y, Clifford CA, Dransfield MT, Bolger GB, Rowe SM: CFTR activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol. 2013, [Epub ahead of print]
Rowe SM, Sloane P, Tang LP, Backer K, Mazur M, Buckley-Lanier J, Nudelman I, Belakhov V, Bebok Z, Schwiebert E, et al: Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med. 2011
Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P: Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med. 2006, 174: 787-794. 10.1164/rccm.200509-1377OC. PubMedPubMedCentralCrossRef
Bombieri C, Giorgi S, Carles S, de Cid R, Belpinati F, Tandoi C, Pallares-Ruiz N, Lazaro C, Ciminelli BM, Romey MC, et al: A new approach for identifying non-pathogenic mutations. An analysis of the cystic fibrosis transmembrane regulator gene in normal individuals. Hum Genet. 2000, 106: 172-178. 10.1007/s004390051025. PubMedCrossRef
- Impact of heterozygote CFTR Mutations in COPD patients with Chronic Bronchitis
S Vamsee Raju
Jody H Tate
Sandra KG Peacock
Robert A Oster
Mark T Dransfield
Steven M Rowe
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II